Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
F-Prime Capital, the venture capital arm of Fidelity Investments, is based in Cambridge, Massachusetts. Founded as Fidelity Biosciences, the firm has evolved to focus on healthcare and technology investments, leveraging Fidelity's extensive resources and expertise. With approximately $4.8 billion in assets under management (AUM), F-Prime Capital operates without the pressure of outside fundraising, allowing it to concentrate fully on supporting entrepreneurs. The firm has a rich history of over 40 years in venture investing, establishing a strong reputation in the industry. F-Prime Capital's unique structure includes small, local teams that are able to tap into Fidelity's global network, providing portfolio companies with unparalleled support and resources. The firm also has a sister fund, Eight Roads, which focuses on investment opportunities in Asia, further expanding its reach and capabilities.
F-Prime Capital specializes in investing in the healthcare and technology sectors, with a particular emphasis on biotech, fintech, SaaS, and therapeutics. The firm adopts a stage-agnostic approach, primarily targeting early-stage investments, including Series A, B, and C rounds. Check sizes typically range from $5 million to $30 million, allowing F-Prime to provide substantial support to its portfolio companies. The firm seeks to partner with innovative startups that are developing transformative technologies and solutions. F-Prime Capital's investment strategy is bolstered by a team of experienced professionals, including scientists and operators, who possess deep domain expertise in their respective fields. This expertise enables the firm to foster scalable growth and drive success for its portfolio companies. By leveraging Fidelity's vast resources, F-Prime Capital is well-positioned to identify and support emerging companies that align with its investment thesis.
F-Prime Capital boasts a notable portfolio that includes high-profile companies such as Alibaba, Atari, MCI, Ironwood Pharmaceuticals, and Ultragenyx. The firm has a proven track record of successful investments, demonstrating its ability to identify and nurture innovative startups. In the past year alone, F-Prime has made 10 investments, showcasing its active engagement in the venture capital landscape. The firm's portfolio reflects its focus on transformative technologies across various sectors, including life sciences and enterprise software. With over 40 years of venture investing experience, F-Prime Capital has established itself as a key player in the industry, consistently delivering value to its investors and portfolio companies alike.
F-Prime Capital Team: The firm comprises a team of experienced professionals with backgrounds in science, technology, and entrepreneurship, enabling them to provide valuable insights and support to portfolio companies.
To pitch F-Prime Capital, founders should prepare a detailed presentation that outlines their business model and growth strategy. While specific submission guidelines are not provided, a well-structured pitch deck is essential for consideration.
F-Prime Capital has been actively investing in innovative companies across various sectors, including biotech, fintech, and SaaS. Their recent investments reflect a commitment to supporting transformative technologies and solutions.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.